Literature DB >> 28223256

Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Edwin Vargas1, Senu Apewokin2, Rajat Madan2.   

Abstract

Clostridium difficile is the leading cause of healthcare-associated infections in the United States. Clinically, C. difficile-associated disease can present as asymptomatic colonization, self-limited diarrheal illness or severe colitis (that may result in death). This variability in disease course and outcomes suggests that host factors play an important role as key determinants of disease severity. Currently, there are several scoring indices to estimate severity of C. difficile-associated disease. Leukocytosis and renal failure are considered to be the most important predictors of C. difficile disease severity in hosts with a normal immune system. The degree of leukocytosis which is considered significant for severe disease and how it is scored vary amongst scoring indices. None of the scores have been prospectively validated, and while total WBC count is useful to estimate the magnitude of the host response in most patient populations, in immune-compromised patients like those receiving chemotherapy, solid organ transplant patients or hematopoietic stem cell transplants the WBC response can be variable or even absent making this marker of severity difficult to interpret. Other cellular subsets like neutrophils, eosinophils and lymphocytes provide important information about the host immune status and play an important role in the immune response against C. difficile infection. However, under the current scoring systems the role of these cellular subsets have been underestimated and only total white blood cell counts are taken into account. In this review we highlight the role of host leukocyte response to C. difficile challenge in the normal and immunocompromised host, and propose possible ways that would allow for a better representation of the different immune cell subsets (neutrophils, lymphocytes and eosinophils) in the current scoring indices.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Disease severity; Leukocytosis

Mesh:

Year:  2017        PMID: 28223256      PMCID: PMC5531608          DOI: 10.1016/j.anaerobe.2017.02.014

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  57 in total

1.  Leukemoid reaction to Clostridium difficile infection.

Authors:  Ashutossh Naaraayan; Melissa Aleta; Prasanta Basak; Stephen Jesmajian; Robert Goldstein
Journal:  Anaerobe       Date:  2015-05-13       Impact factor: 3.331

2.  Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis.

Authors:  Van Trung Chu; Alexander Beller; Sebastian Rausch; Julia Strandmark; Michael Zänker; Olga Arbach; Andrey Kruglov; Claudia Berek
Journal:  Immunity       Date:  2014-04-17       Impact factor: 31.745

3.  A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

Authors:  M Catherine McEllistrem; Robert J Carman; Dale N Gerding; C W Genheimer; L Zheng
Journal:  Clin Infect Dis       Date:  2004-12-15       Impact factor: 9.079

4.  Human neutrophils are activated by a peptide fragment of Clostridium difficile toxin B presumably via formyl peptide receptor.

Authors:  Sebastian D Goy; Alexandra Olling; Detlef Neumann; Andreas Pich; Ralf Gerhard
Journal:  Cell Microbiol       Date:  2015-01-26       Impact factor: 3.715

5.  Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis.

Authors:  Ruihong Luo; Alan Greenberg; Christian D Stone
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03-24       Impact factor: 3.254

6.  Clostridium difficile infection in patients with unexplained leukocytosis.

Authors:  Anna Wanahita; Elizabeth A Goldsmith; Bernard J Marino; Daniel M Musher
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

7.  Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection.

Authors:  Erica L Buonomo; Carrie A Cowardin; Madeline G Wilson; Mahmoud M Saleh; Patcharin Pramoonjago; William A Petri
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

8.  Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.

Authors:  S G Krishna; W Zhao; S K Apewokin; K Krishna; P Chepyala; E J Anaissie
Journal:  Transpl Infect Dis       Date:  2013-08-27       Impact factor: 2.228

9.  Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.

Authors:  Martijn P Bauer; Marjolein P M Hensgens; Mark A Miller; Dale N Gerding; Mark H Wilcox; Adam P Dale; Warren N Fawley; Ed J Kuijper; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Eosinophils from Murine Lamina Propria Induce Differentiation of Naïve T Cells into Regulatory T Cells via TGF-β1 and Retinoic Acid.

Authors:  Hong-Hu Chen; Ai-Hua Sun; David M Ojcius; Wei-Lin Hu; Yu-Mei Ge; Xu'ai Lin; Lan-Juan Li; Jian-Ping Pan; Jie Yan
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

View more
  3 in total

Review 1.  Targeting Clostridium difficile Surface Components to Develop Immunotherapeutic Strategies Against Clostridium difficile Infection.

Authors:  Séverine Péchiné; Jean F Bruxelle; Claire Janoir; Anne Collignon
Journal:  Front Microbiol       Date:  2018-05-23       Impact factor: 5.640

2.  The Traditional Chinese Medicine Fufang Shatai Heji (STHJ) Enhances Immune Function in Cyclophosphamide-Treated Mice.

Authors:  Kai-Jian Fan; Yun-Wu Li; Jing Wu; Jun Li; Jun Zhang; Qi-Shan Wang; Bing-Xin Xu; Qing Cai; Ting-Yu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-23       Impact factor: 2.629

3.  Serum Sphingosine-1-phosphate level and peritonitis in peritoneal dialysis patients.

Authors:  Qiong Bai; Hong-Xia Guo; Chun-Yan Su; Qing-Feng Han; Tao Wang; Wen Tang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.